Nordisk
Novo Nordisk Acquires 2seventy’s Gene Editing Technology and Haemophilia Candidate for $40 Million
Novo Nordisk, 2seventy, gene editing, haemophilia, MegaTAL, in vivo gene editing technology
Novo Nordisk Invests $4.1 Billion in New US Manufacturing Site, Abandoning Irish Plans
Novo Nordisk, US manufacturing site, obesity drugs, fill-finish facility, Clayton, NC, Irish build
Novo Nordisk Wins Approval in China for GLP-1 Obesity Drug Wegovy
Novo Nordisk, Wegovy, GLP-1, Obesity, China, Weight Loss, Semaglutide, Ozempic
Eli Lilly’s Zepbound Shows Promise in Treating Sleep Apnea, Seeks FDA Approval
Zepbound, Eli Lilly, sleep apnea, FDA approval, Novo Nordisk, Wegovy, weight loss, diabetes, pharmaceuticals
Eli Lilly Invests $5.3 Billion in Indiana Plant to Boost Diabetes and Obesity Drug Production ###
Eli Lilly, Diabetes, Obesity, Mounjaro, Zepbound, Tirzepatide, Indiana, Manufacturing, API, Novo Nordisk, GLP-1 drugs
Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering
Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis
Ozempic Reduces Mortality Risk by 20% in Diabetes Patients with Chronic Kidney Disease
** Ozempic, Novo Nordisk, diabetes, chronic kidney disease, mortality risk, cardiovascular deaths, kidney failure, semaglutide, Wegovy, obesity treatment
Lilly’s Weekly Insulin Therapy Excels in Two Major Clinical Trials, Narrowing Gap with Novo Nordisk
Lilly, Novo Nordisk, weekly insulin, primary endpoint, pivotal trials, diabetes management, insulin therapy, clinical trials, diabetes treatment, pharmaceutical industry.
Novo Nordisk’s Wegovy Shines as a Promising Obesity Treatment: A 4-Year Analysis
Novo Nordisk, Wegovy, obesity treatment, weight loss, 4-year data, clinical trials, blockbuster drug, GLP-1 receptor agonist, FDA approval, semaglutide.
Novo Nordisk’s Wegovy Demonstrates Long-Term Weight Loss Success in New Analysis
Novo Nordisk, Wegovy, weight loss, long-term, four years, analysis, obesity treatment, semaglutide, sustained weight loss, diabetes, cardiovascular disease.